Oxymetazoline/tetracaine intranasal - St. Renatus

Drug Profile

Oxymetazoline/tetracaine intranasal - St. Renatus

Alternative Names: Kovacaine; Kovacaine Mist; KOVANAZE; Oxymetazoline hydrochloride/tetracaine hydrochloride; Tetracaine hydrochloride/oxymetazoline hydrochloride; Tetracaine/oxymetazoline intranasal - St. Renatus

Latest Information Update: 14 Jul 2016

Price : $50

At a glance

  • Originator St. Renatus
  • Class Aminobenzoic acids; Decongestants; Imidazoles; Local anaesthetics; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Dental pain

Most Recent Events

  • 29 Jun 2016 Registered for Dental pain (Prevention) in USA (Intranasal)
  • 05 Jun 2015 St. Renatus terminates a phase III trial in Dental pain (Prevention, In adults) in USA (NCT01660893) before June 2015
  • 18 Mar 2014 St. Renatus announces its intention to submit an NDA for oxymetazoline/tetracaine intranasal, as a needle-free alternative for anaesthesia of maxillary teeth for use in paediatric and adult patients, to the US FDA in 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top